Is Pharma having a value conversation while Payers want a value demonstration?
On June 16 I held this presentation about the differences in perspectives between Pharma and Payers when appraising the value of innovative medicines at the 6th Pharma, Reimbursement & Market Access congres 2022 in Boston Massachusetts.
A very relevant discussion as the increasing introductions of precision medicines are introducing new complexities in health technology assessment creating an innovation paradox.
Companies planning to launch these products in the coming years face the challenge of having to place big bets on an uncertain future which requires rethinking of the critical capabilities needed at multiple levels in their organization.